EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex

Bowen Yao, Ye Lu, Yazhao Li, Yixue Bai, Xinyu Wei, Yuanyuan Yang, Demao Yao

Cancer Immunology, Immunotherapy · 2023-12 · 72 (12) · 4279-4292

DOI: 10.1007/s00262-023-03563-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 31.10.2023. Verfasst von Bowen Yao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research and Development Program Fund of Shaanxi Province, Hospital Research and Development Fund of the First Affiliated Hospital of Xi'an Jiaotong University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bcl-2-associated transcription factor-1 (BCLAF1), an apoptosis-regulating protein of paramount significance, orchestrates the progression of various malignancies. This study reveals increased BCLAF1 expression in hepatocellular carcinoma (HCC) patients, in whom elevated BCLAF1 levels are linked to escalated tumor grades and diminished survival rates. Moreover, novel BCLAF1 expression is particularly increased in HCC patients who were not sensitive to the combined treatment of atezolizumab and bevacizumab, but not in patients who had tumors that responded to the combined regimen. Notably, overexpression of BCLAF1 increases HCC cell proliferation in vitro and in vivo, while the conditioned medium derived from cells overexpressing BCLAF1 strikingly enhances the tube-formation capacity of human umbilical vein endothelial cells. Furthermore, compelling evidence demonstrates that BCLAF1 attenuates the expression of prolyl hydroxylase domain protein 2 (PHD2) and governs the stability of hypoxia-inducible factor-1 α (HIF-1 α ) under normoxic conditions without exerting any influence on transcription, as determined by Western blot and RT‒qPCR analyses. Subsequently, employing coimmunoprecipitation and immunofluorescence, we validated the reciprocal interaction between BCLAF1 and Cullin 3 (CUL3), through which BCLAF1 actively upregulates the ubiquitination and degradation of PHD2. The Western blot and RT‒qPCR results suggests that programmed death ligand-1 (PD-L1) is one of the downstream responders to HIF-1 α in HCC. Thus, we reveal the pivotal role of BCLAF1 in promoting PD-L1 transcription and, through binding to CUL3, in promoting the accumulation of HIF-1 α under normoxic conditions, thereby facilitating the ubiquitination and degradation of PHD2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansB7-H1 AntigenCell LineCullin ProteinsEndothelial CellsHypoxia-Inducible Factor 1, alpha SubunitRepressor ProteinsTumor Suppressor Proteins

Stichwörter der Autor:innen

AtezolizumabBCLAF1HIF-1αHepatocellular carcinomaImmunotherapyPD-L1

Substanzen

B7-H1 AntigenBCLAF1 protein, humanCUL3 protein, humanCullin ProteinsHypoxia-Inducible Factor 1, alpha SubunitRepressor ProteinsTumor Suppressor ProteinsHIF1A protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Center for Translational Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Xi'an Jiaotong University Health Science Center, Xi'an, China.
  • Department of Geriatric Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. ydm_723@163.com.

Förderung

  • Research and Development Program Fund of Shaanxi Province
  • Hospital Research and Development Fund of the First Affiliated Hospital of Xi'an Jiaotong University
  • National Natural Science Foundation of China
  • Hospital Research and Development Fund of the First Affiliated Hospital of Xi’an Jiaotong University

Zitieren

APA

Yao, B., Lu, Y., Li, Y., Bai, Y., Wei, X., Yang, Y., & Yao, D. (2023). BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex. Cancer Immunology, Immunotherapy, 72(12), 4279-4292. https://doi.org/10.1007/s00262-023-03563-8

Vancouver

Yao B, Lu Y, Li Y, Bai Y, Wei X, Yang Y, et al. BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex. Cancer Immunology, Immunotherapy. 2023;72(12):4279-4292. doi:10.1007/s00262-023-03563-8

BibTeX
@article{Yao2023,
  author = {Yao, Bowen and Lu, Ye and Li, Yazhao and Bai, Yixue and Wei, Xinyu and Yang, Yuanyuan and Yao, Demao},
  title = {BCLAF1-induced HIF-1α accumulation under normoxia enhances PD-L1 treatment resistances via BCLAF1-CUL3 complex},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  volume = {72},
  number = {12},
  pages = {4279--4292},
  doi = {10.1007/s00262-023-03563-8}
}
Kostenlos starten →